BioCentury
ARTICLE | Financial News

Inotrem raises €39M series B for septic shock therapy, diagnostic

September 12, 2019 11:45 PM UTC

A €39 million ($43 million) series B round raised by Inotrem will allow the French biotech to get its lead program for septic shock through Phase IIb testing.

Morningside Ventures led the round, with participation from new investor Invus and existing investors Andera Partners, Sofinnova Partners and BiomedInvest...